Ophthalmologica· 2017Q2· Guideline
Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)
- 708citations
- Q2SCImago
- 2017year
Short summary
Anti-VEGF therapy is now the first-line treatment for diabetic macular edema (DME), replacing laser photocoagulation, with steroids reserved for persistent cases.
AI-generated from the title and abstract; the full text is not read.
Key points
- Anti-VEGF therapy is the recommended first-line treatment for DME.
- Laser photocoagulation is no longer the primary treatment for DME.
- Steroids are indicated for chronically persistent DME.
- Guidelines reflect updated knowledge and diagnostic/therapeutic advances.
AI-generated from the title and abstract; the full text is not read.
Abstract
Diabetic retinal disease is envisioned to become the plague of the coming decades with a steep increase of worldwide diabetes incidence followed by a substantial rise in retinal disease. Improvements in diagnostic and therapeutic care have to cope with this dilemma in a clinically and socioeconomically efficient manner. Laser treatment has found a less destructive competitor in pharmacological treatments. As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of diabetic macular edema (DME), and anti-vascular endothelial growth factor therapy has emerged as first-line therapy. Steroids have maintained a role in the management of chronically persistent DME. The paradigm shifts in therapy are accompanied by a substantial break-through in diagnostics. The following guidance for the management of DME has been composed from the best updated knowledge of leading experts in Europe and represents another volume in the series of EURETINA recommendations for the management of retinal disease.
The authors' abstract, as published at the source. Ophthalmologica, 2017 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Ophthalmology
OphthalmologyMedicine